WO2014108921A2 - Dispersion solide de phosphate de carvédilol - Google Patents

Dispersion solide de phosphate de carvédilol Download PDF

Info

Publication number
WO2014108921A2
WO2014108921A2 PCT/IN2014/000022 IN2014000022W WO2014108921A2 WO 2014108921 A2 WO2014108921 A2 WO 2014108921A2 IN 2014000022 W IN2014000022 W IN 2014000022W WO 2014108921 A2 WO2014108921 A2 WO 2014108921A2
Authority
WO
WIPO (PCT)
Prior art keywords
solid dispersion
carvedilol phosphate
pharmaceutically acceptable
carvedilol
amorphous
Prior art date
Application number
PCT/IN2014/000022
Other languages
English (en)
Other versions
WO2014108921A3 (fr
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Kesireddy Subash Chander Reddy
Bandi Vamsi Krishna
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2014108921A2 publication Critical patent/WO2014108921A2/fr
Publication of WO2014108921A3 publication Critical patent/WO2014108921A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • the present invention provides a novel amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
  • Carvedilol and its phosphate salt are antihypertensive agents, which were disclosed in U.S. Patent No. 4,503,067.
  • Carvedilol is known by the chemical name 1- (9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propanol and has the structural formula:
  • Carvedilol phosphate is a nonselective beta blocker/alpha-1 blocker indicated in the treatment of mild to severe congestive heart failure (CHF).
  • CHF mild to severe congestive heart failure
  • the generic name carvedilol phosphate is marketed by SB PHARMCO under the brand name COREG CR ® .
  • Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
  • polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
  • Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
  • XRD X-ray diffraction
  • DSC Differential Scanning Calorimetry
  • IR Infrared spectrometry
  • Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
  • Carvedilol and its phosphate salt can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
  • U.S. patent no. 7,268,156 disclosed crystalline Form I of carvedilol dihydrogen phosphate hemihydrate.
  • Form N Form O, Form P, Form F, Form F l , Form R, Form Y, Form W and Form F2 of carvedilol dihydrogen phosphate.
  • amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier.
  • the amorphous solid dispersion of carvedilol phosphate is stable, reproducible and so, the amorphous solid dispersion of carvedilol phosphate is suitable for formulating carvedilol phosphate.
  • Normally amorphous Forms are hygroscopic.
  • Amorphous solid dispersion of carvedilol phosphate is found to be non-hygroscopic.
  • an object of the present invention is to provide a novel amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
  • the present invention provides amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier.
  • the present invention there is provided a process for the preparation of amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier, which comprises:
  • compositions comprising a therapeutically effective amount of amorphous solid dispersion of carvedilol phosphate along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
  • Figure 1 is a powder X-ray diffractogram patterns of amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier.
  • Powder X-ray diffraction spectrum was measured on a bruker AXS D8 advance powder X-ray diffractometer having a copper- ⁇ radiation. Approximately 500 mg of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two- theta, at 0.020 degrees two theta per step and a step time of 1 second. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 kV and current 35 m A.
  • room temperature refers to temperature at about 25 to 35°C.
  • amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier there is provided amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier.
  • the powdered x-ray diffractogram (PXRD) of amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier is shown in figure 1.
  • Amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier obtained according to the present invention typically has the water content of less than 10 % by weight of the product obtained, preferably the water content of less than 5 % by weight as determined by Karl fisher method.
  • Amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier having enhanced stability, dissolution properties that can be easily formulated into pharmaceutical compositions.
  • the pharmaceutically acceptable carriers may be one or more of copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus.
  • the said pharmaceutically acceptable carriers are used to facilitate the presence of an amorphous carvedilol phosphate.
  • solid dispersion refers to a composition prepared by dissolving or dispersing a substituted carvedilol phosphate in an organic solvent or mixture of organic solvents with one or more pharmaceutically acceptable carriers and converting the solution or dispersion to a solid form.
  • a process for the preparation of amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier which comprises:
  • Carvedilol phosphate used in step (a) may preferably be carvedilol phosphate obtained by the known process.
  • the solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, dimethylformamide, methanol, ethanol, isopropanol, n-butanol, n-pentanol, methylene chloride, chloroform, carbontetrachloride and ethylene dichloride. More preferably the solvents are methylene chloride, dimethyl sulfoxide, dimethylacetamide, dimethylformamide and methanol.
  • the pharmaceutically acceptable carriers used in step (a) may be selected from copovidone, soluplus or hydroxypropyl methylcellulose.
  • the solvent may be removed from the solution in step (b) by known methods, for example, distillation or spray drying.
  • the distillation of the solvent may be carried out at atmospheric pressure or at reduced pressure.
  • the distillation may preferably be carried out until the solvent is almost completely distilled off.
  • reduced pressure refers to a pressure of less than 100 mmHg.
  • spray drying refers to is a method of producing a dry powder from a liquid or slurry by rapidly drying with a hot gas.
  • compositions comprising a therapeutically effective amount of amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier and along with a pharmaceutically acceptable excipients, and at least one pharmaceutically acceptable excipient.
  • the amorphous solid dispersion of carvedilol phosphate in combination with a pharmaceutically acceptable carrier may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
  • the present invention provides a pharmaceutical composition containing said solid dispersion along with the pharmaceutically acceptable excipients such as diluents, chelating agents, disintegrant, glidant, binders, surfactants, coloring agents and/or lubricants.
  • pharmaceutically acceptable excipients such as diluents, chelating agents, disintegrant, glidant, binders, surfactants, coloring agents and/or lubricants.
  • binders include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, and the like.
  • diluents include calcium carbonate, calcium phosphate- dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sorbitol, starch, starch pregelatinized, sucrose, sugar compressible, sugar confectioners, and the like and mixtures thereof.
  • Surfactants include both non-ionic and ionic (cationic, anionic and zwitterionic) surfactants suitable for use in pharmaceutical dosage forms. These include polyethoxylated fatty acids and its derivatives, for example, polyethylene glycol 400 distearate, polyethylene glycol-20 dioleate, polyethylene glycol 4 - 150 mono dilaurate, and polyethylene glycol - 20 glyceryl stearate; alcohol - oil transesterification products, for example, polyethylene glycol - 6 corn oil; polyglycerized fatty acids, for example, polyglyceryl - 6 pentaoleate; propylene glycol fatty acid esters, for example, propylene glycol monocaprylate; mono and diglycerides, for example, glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and its derivatives, for example, polyethylene glycol - 20 sorbitan monooleate and sorbitan mp
  • disintegrants include low-substituted hydroxypropylcellulose (L-HPC), sodium starch glycollate, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, croscarmellose sodium A-type (Ac-di-sol), starch, crystalline cellulose, hydroxypropyl starch, pregelatinized starch, and the like and mixtures thereof.
  • lubricants/glidants include colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and the like and mixtures thereof.
  • Coloring agents include any FDA approved colors for oral use.
  • a mixture of carvedilol phosphate (50 gm) as obtained in example 1 and copovidone (25 gm) was dissolved in a mixture of methanol (1000 ml) and methylene chloride (100 ml) at room temperature. The contents were heated to 35 to 40°C for 20 minutes and filtered through celite bed. The solvent was distilled off under reduced pressure at below 50°C to obtain 73 gm of amorphous carvedilol phosphate solid dispersion with copovidone. The amorphous carvedilol phosphate solid dispersion with copovidone obtained was stabilized in stability chamber at the temperature of 40°C under relative humidity of 75%.
  • Example 2 was repeated using dimethylformamide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with copovidone.
  • Example 2 was repeated using dimethylacetamide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with copovidone.
  • Example 2 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with copovidone.
  • Example 2 was repeated using ethanol solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with copovidone.
  • Example 9 was repeated using dimethylformamide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with hydroxypropyl methylcellulose.
  • Example 9 was repeated using dimethylacetamide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with hydroxypropyl methylcellulose.
  • Example 9 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with hydroxypropyl methylcellulose.
  • Example 13 Preparation of amorphous carvedilol phosphate solid dispersion with hydroxypropyl methylcellulose
  • Example 9 was repeated using ethanol solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with hydroxypropyl methylcellulose.
  • a mixture of carvedilol phosphate (10 gm) and soluplus (10 gm) was dissolved in a mixture of methanol (1200 ml) and methylene chloride (120 ml) at room temperature. The contents were heated to 35 to 40°C for 20 minutes and filtered through celite bed. The solvent was distilled off under reduced pressure at below 50°C to obtain 18 gm of amorphous carvedilol phosphate solid dispersion with soluplus. The amorphous carvedilol phosphate solid dispersion with soluplus obtained was stabilized in stability chamber at the temperature of 40°C under relative humidity of 75%.
  • Example 14 was repeated using dimethylformamide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with soluplus.
  • Example 14 was repeated using dimethylacetamide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with soluplus.
  • Example 14 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with soluplus.
  • Example 18 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with soluplus.
  • Example 14 was repeated using ethanol solvent instead of methanol solvent to obtain amorphous carvedilol phosphate solid dispersion with soluplus.
  • a mixture of carvedilol phosphate (5 gm) and ethyl cellulose (5 gm) was dissolved in a mixture of methanol (1000 ml) and methylene chloride (100 ml) at room temperature. The contents were heated to 35 to 40°C for 20 minutes and filtered through celite bed. The solvent was distilled off under reduced pressure at below 50°C to obtain 8 gm of amorphous carvedilol phosphate solid dispersion with ethyl cellulose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une nouvelle dispersion solide amorphe de phosphate de carvédilol en association avec un vecteur pharmaceutiquement acceptable, sur un procédé pour sa préparation et sur des compositions pharmaceutiques la comprenant.
PCT/IN2014/000022 2013-01-10 2014-01-09 Dispersion solide de phosphate de carvédilol WO2014108921A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ININ159/CHE/2013 2013-01-10
IN159CH2013 2013-01-10

Publications (2)

Publication Number Publication Date
WO2014108921A2 true WO2014108921A2 (fr) 2014-07-17
WO2014108921A3 WO2014108921A3 (fr) 2015-04-02

Family

ID=51167479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000022 WO2014108921A2 (fr) 2013-01-10 2014-01-09 Dispersion solide de phosphate de carvédilol

Country Status (1)

Country Link
WO (1) WO2014108921A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002683A2 (fr) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Carvédilol phosphate
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof

Also Published As

Publication number Publication date
WO2014108921A3 (fr) 2015-04-02

Similar Documents

Publication Publication Date Title
WO2014076712A2 (fr) Dispersion solide de chlorhydrate de lurasidone
WO2014118808A2 (fr) Dispersion solide de ticagrelor
US9624172B2 (en) Polymorphs of lomitapide and its salts
US20040010151A1 (en) Lansoprazole polymorphs and processes for preparation thereof
US20190241530A1 (en) Crystal form of ozanimod, and preparation method and pharmaceutical composition thereof
WO2013160916A1 (fr) Dispersion solide de malate de sunitinib
RU2716260C2 (ru) Кристаллическая форма бисульфатного ингибитора jak-киназы и способ ее получения
US20170296570A1 (en) High Drug Load Tablets Comprising Sofosbuvir
JP6887980B2 (ja) 薬学的に活性な化合物の固体形態
WO2014115169A2 (fr) Dispersion solide de crizotinib
JP2005534633A (ja) ガチフロキサシンの新規結晶形
WO2013171766A2 (fr) Dispersion solide de saxagliptine
WO2014108921A2 (fr) Dispersion solide de phosphate de carvédilol
WO2014174529A2 (fr) Polymorphes d'avanafil
US20150141457A1 (en) Elvitegravir solid dispersion
KR102100357B1 (ko) 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물
US7777049B2 (en) Crystalline forms of Rizatriptan benzoate
WO2014013505A2 (fr) Vildagliptine amorphe
WO2014102832A2 (fr) Dispersion solide de chlorhydrate de saxagliptine
WO2013164857A1 (fr) Dispersion solide de succinate de desvenlafaxine
JP2023553457A (ja) 非晶質固体分散体
WO2013179305A1 (fr) Dispersion solide d'ibandronate de sodium
US20170369475A1 (en) Flibanserin Hydrate
CA2829186A1 (fr) Forme amorphe d'un melange de lopinavir et de ritonavir
NZ727829B2 (en) Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition containing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14738254

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct app. not ent. europ. phase

Ref document number: 14738254

Country of ref document: EP

Kind code of ref document: A2